Resmed Inc Stock EBITDA
| RMD Stock | USD 180.35 1.50 0.84% |
ResMed Inc fundamentals help investors to digest information that contributes to ResMed's financial success or failures. It also enables traders to predict the movement of ResMed Stock. The fundamental analysis module provides a way to measure ResMed's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ResMed stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | 1.5 B | 1.6 B |
ResMed | EBITDA |
ResMed Inc Company EBITDA Analysis
ResMed's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current ResMed EBITDA | 1.34 B |
Most of ResMed's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ResMed Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ResMed EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for ResMed is extremely important. It helps to project a fair market value of ResMed Stock properly, considering its historical fundamentals such as EBITDA. Since ResMed's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ResMed's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ResMed's interrelated accounts and indicators.
Click cells to compare fundamentals
ResMed EBITDA Historical Pattern
Today, most investors in ResMed Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ResMed's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's ebitda growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of ResMed ebitda as a starting point in their analysis.
ResMed EBITDA |
| Timeline |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
ResMed Ebitda
Ebitda |
|
According to the company disclosure, ResMed Inc reported earnings before interest,tax, depreciation and amortization of 1.34 B. This is 52.67% higher than that of the Health Care Equipment & Supplies sector and 184.73% higher than that of the Health Care industry. The ebitda for all United States stocks is 65.64% higher than that of the company.
ResMed EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ResMed's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ResMed could also be used in its relative valuation, which is a method of valuing ResMed by comparing valuation metrics of similar companies.ResMed is currently under evaluation in ebitda category among related companies.
ResMed ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ResMed's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ResMed's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
ResMed Institutional Holders
Institutional Holdings refers to the ownership stake in ResMed that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ResMed's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ResMed's value.| Shares | Bank Of New York Mellon Corp | 2023-12-31 | 1.2 M | Legal & General Group Plc | 2023-12-31 | 1.1 M | Charles Schwab Investment Management Inc | 2023-12-31 | 863.3 K | Fidelity International Ltd | 2023-12-31 | 840 K | Jpmorgan Chase & Co | 2023-12-31 | 733.4 K | Lgt Capital Partners Ltd. | 2023-12-31 | 683.8 K | Voloridge Investment Management, Llc | 2023-09-30 | 662.4 K | D. E. Shaw & Co Lp | 2023-09-30 | 657.3 K | Amundi | 2023-12-31 | 615 K | Vanguard Group Inc | 2023-12-12 | 17.7 M | Blackrock Inc | 2023-12-31 | 12.2 M |
ResMed Fundamentals
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.20 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 27.48 B | ||||
| Shares Outstanding | 147.09 M | ||||
| Shares Owned By Insiders | 0.81 % | ||||
| Shares Owned By Institutions | 57.22 % | ||||
| Number Of Shares Shorted | 7.89 M | ||||
| Price To Earning | 73.48 X | ||||
| Price To Book | 6.10 X | ||||
| Price To Sales | 6.07 X | ||||
| Revenue | 4.22 B | ||||
| Gross Profit | 2.39 B | ||||
| EBITDA | 1.34 B | ||||
| Net Income | 897.56 M | ||||
| Cash And Equivalents | 273.71 M | ||||
| Cash Per Share | 1.87 X | ||||
| Total Debt | 1.58 B | ||||
| Debt To Equity | 0.27 % | ||||
| Current Ratio | 2.80 X | ||||
| Book Value Per Share | 30.47 X | ||||
| Cash Flow From Operations | 693.3 M | ||||
| Short Ratio | 6.91 X | ||||
| Earnings Per Share | 6.05 X | ||||
| Price To Earnings To Growth | 1.75 X | ||||
| Target Price | 202.68 | ||||
| Beta | 0.67 | ||||
| Market Capitalization | 26.31 B | ||||
| Total Asset | 6.75 B | ||||
| Retained Earnings | 4.25 B | ||||
| Working Capital | 1.61 B | ||||
| Current Asset | 1.42 B | ||||
| Current Liabilities | 637.99 M | ||||
| Annual Yield | 0.01 % | ||||
| Five Year Return | 1.02 % | ||||
| Net Asset | 6.75 B | ||||
| Last Dividend Paid | 1.84 |
About ResMed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ResMed Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ResMed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ResMed Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether ResMed Inc is a strong investment it is important to analyze ResMed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ResMed's future performance. For an informed investment choice regarding ResMed Stock, refer to the following important reports:Check out ResMed Piotroski F Score and ResMed Altman Z Score analysis. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for ResMed Stock analysis
When running ResMed's price analysis, check to measure ResMed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ResMed is operating at the current time. Most of ResMed's value examination focuses on studying past and present price action to predict the probability of ResMed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ResMed's price. Additionally, you may evaluate how the addition of ResMed to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| CEOs Directory Screen CEOs from public companies around the world |
Is ResMed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ResMed. If investors know ResMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ResMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.07) | Dividend Share 1.84 | Earnings Share 6.05 | Revenue Per Share 30.633 | Quarterly Revenue Growth 0.125 |
The market value of ResMed Inc is measured differently than its book value, which is the value of ResMed that is recorded on the company's balance sheet. Investors also form their own opinion of ResMed's value that differs from its market value or its book value, called intrinsic value, which is ResMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ResMed's market value can be influenced by many factors that don't directly affect ResMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ResMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if ResMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ResMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.